Crossmark

Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study

Crossref DOI link: https://doi.org/10.1007/s11136-026-04193-0

Published Online: 2026-03-01

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Urru, Silvana A. M. https://orcid.org/0000-0001-6213-1290
Mayer, Flavia

Spila Alegiani, Stefania

Paoloni, Francesca

Guella, Anna

Murru, Roberta

Bucaneve, Giampaolo

Formoso, Giulio

Racanelli, Vito

Forti, Anna

Fozza, Claudio

Longo, Giuseppe

Fulgenzio, Chiara

Musicco, Felice

Campomori, Annalisa

,
Funding

Funding for this research was provided by:

Agenzia Italiana del Farmaco, Ministero della Salute

Agenzia Italiana del Farmaco, Ministero della Salute,Italy
License Information

Text and Data Mining valid from 2026-03-01

Version of Record valid from 2026-03-01
More Information

Article History

Received: 22 September 2025

Accepted: 2 February 2026

First Online: 1 March 2026

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below